Perspective Therapeutics Ships First Products from Cutting-Edge Radiopharma Facility in New Jersey

Perspective Therapeutics, Inc., a company specializing in manufacturing radiopharmaceuticals for cancer treatment, has announced its 1st successful shipment and patient dosing from its second manufacturing facility in Somerset, New Jersey. The company marked its first shipment with the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. 

This facility will function to supply investigational products supporting clinical studies for VMT-α-NET. This new facility, located in Somerset, New Jersey,  joins the existing plant in Coralville, Iowa, which has been operational in producing the Company's investigational products for over 15 months.

The new facility is equipped with three manufacturing suites that are compliant with Current Good Manufacturing Practice (cGMP) standards. It is anticipated to fulfil future clinical trials and commercial needs for cancer treatment centres in the Northeastern U.S. The facility was operated by Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company, before its acquisition by Perspective in March 2024. The facility formerly was responsible for producing Azedra, a radioactive iodine treatment approved by the U.S. FDA in 2018 for rare adrenal tumors.

Shane Cobb, Perspective's Executive Vice President of Operations, stated, "Today marks an exciting milestone as we start shipping investigational products from this state-of-the-art facility. Going operational seven months after taking possession of the facility allows us to accelerate our efforts in delivering investigational products and, pending approval, new radiopharmaceutical therapies."

Thijs Spoor, Perspective's Chief Executive Officer, said in a statement, "We are thrilled to celebrate the opening of this facility, which is a step forward in building out our manufacturing and supply chain capabilities," also continued saying, "It reflects our commitment to delivering targeted alpha-particle therapies to patients in critical need. Our network approach aligns with patient interest and the half-life profiles of isotopes contained in our investigational products. We look forward to replicating this effort and adding sites strategically to enhance our network to support key treatment hubs across the U.S."